#brainwavespredictssrisideeffects — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #brainwavespredictssrisideeffects, aggregated by home.social.
-
DATE: September 17, 2026 at 08:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Brain waves predict sexual side effects of common depression medications
URL: https://www.psypost.org/brain-waves-predict-sexual-side-effects-of-common-depression-medications/
Measuring brain activity before starting depression medication might help doctors predict which patients will experience sexual side effects. A recent study shows that a specific brain wave pattern related to serotonin can forecast whether a patient will struggle to reach orgasm after taking common antidepressants. The research was published in the Journal of Psychiatric Research.
Depression often brings a host of challenging symptoms, with sexual difficulties being highly prevalent. Between 40 and 60 percent of people with major depressive disorder experience sexual disturbances as part of their condition. While treating depression can sometimes improve a person’s sex life as their mood lifts, the medications themselves frequently cause new problems.
Selective serotonin reuptake inhibitors, usually referred to as SSRIs, are the most common medications prescribed for depression. SSRIs work by increasing the availability of serotonin, a chemical messenger in the brain. Higher serotonin levels help alleviate depressive symptoms but also inhibit sexual function in many individuals.
Between 40 and 70 percent of patients taking SSRIs report adverse reactions such as diminished sexual desire, difficulty becoming aroused, or trouble reaching orgasm. These side effects can drastically affect a person’s quality of life and relationships. As a result, many patients stop taking their antidepressants altogether.
The study was conducted by researchers at the Copenhagen University Hospital and the University of Copenhagen. Gudrun Dilja Ketilsdottir and Kristian H. Reveles Jensen led the research team. They wanted to find a way to predict individual susceptibility to these side effects before a prescription is written.
The researchers focused on a biological marker called the loudness dependence of auditory evoked potentials. This marker is measured using an electroencephalogram, or EEG, which records electrical activity in the brain through sensors placed on the scalp. The measure tracks how the brain reacts to sounds of increasing volume.
Previous research suggests that this auditory brain response acts as an inverse indicator of serotonin activity in the central nervous system. A weaker brain response to louder sounds indicates higher baseline serotonin activity. The researchers hypothesized that people who already have high serotonin activity before starting medication might be pushed over a threshold by SSRIs, triggering sexual side effects.
The research team analyzed data from 90 unmedicated patients diagnosed with major depressive disorder. The participants were between the ages of 18 and 57, and roughly three-quarters of the group were women. None of the patients had taken antidepressant medication for at least two months prior to the study.
Before starting any treatment, each participant underwent an EEG recording. During this session, they listened to a series of tones at five different volume levels, ranging from 60 to 100 decibels. The researchers calculated the auditory brain response for each patient based on how their brain waves changed as the tones grew louder.
Alongside the brain scans, the researchers assessed each patient’s baseline sexual function using clinical questionnaires. They also measured blood levels of testosterone. Afterward, 86 of the participants began treatment with the SSRI escitalopram for eight weeks.
During the treatment period, clinicians monitored the patients for changes in their depression symptoms and the emergence of side effects. If a patient did not respond well to escitalopram or experienced intolerable side effects by week four, they were offered a switch to a different type of antidepressant called duloxetine. Seven patients made this switch.
At the end of the eight weeks, the clinicians formally rated the severity of any medication-induced sexual side effects. The researchers then ran statistical models to see if the pretreatment brain wave measurements corresponded to the side effects observed at the end of the trial.
The analysis revealed a robust link between baseline brain activity and later sexual difficulties. Patients who displayed a weaker brain response to increasing sound volume prior to treatment experienced higher rates of SSRI-induced orgasmic dysfunction. This specific brain wave pattern accurately predicted distressing orgasmic dysfunction 87 percent of the time.
The researchers also looked at whether the brain marker could predict a loss of sexual desire. They found a marginal association between the brain response and decreased libido, though it was not as strong as the link to orgasmic dysfunction. The brain marker was entirely unrelated to the occurrence of erectile dysfunction in the male participants.
When the team incorporated pretreatment blood testosterone levels into their predictive models, the changes in accuracy were not statistically significant. The auditory brain response alone, combined with basic demographic information and the patient’s baseline sexual function, was sufficient for predicting the side effects.
The researchers also examined the participants’ sexual function before any medication was introduced. They found that the auditory brain response was not associated with the level of sexual dysfunction caused directly by the depression itself. The brain marker appears specifically linked to how the body reacts to the introduction of the SSRI medication.
Because the biological mechanism for orgasm relies heavily on specific serotonin receptors, the researchers suggest that the brain marker is capturing the precise neurological pathway disrupted by SSRIs. In contrast, sexual desire involves a wider network of brain chemicals, which might explain why the brain marker was less predictive of decreased libido.
The study relied on an open-label design, meaning both the patients and the clinicians knew which medication was being administered. Without a placebo control group, some of the observed changes in sexual function could be related to natural fluctuations in the illness rather than the medication alone. The study participants were also relatively young, with an average age of 27.5 years, which may limit how well the findings apply to older adults.
Because a small portion of the group switched from escitalopram to duloxetine halfway through the trial, the results capture the effects of two different antidepressants. The researchers did perform a secondary analysis isolating only the patients on escitalopram, which produced the same outcome. Even so, testing the brain marker against a single medication in a more standardized protocol would provide firmer conclusions.
Moving forward, the research team aims to test this biological marker in more diverse groups of patients in standard clinical settings. If the auditory brain response proves reliable across broader populations, it could eventually serve as a routine screening tool. Doctors could use the test to identify patients at high risk for sexual side effects and prescribe alternative antidepressants that act on different brain chemicals.
The study, “Serotonergic activity estimated by EEG loudness-dependent auditory evoked potentials as a predictor of sexual SSRI side effects,” was authored by Gudrun Dilja Ketilsdottir, Cheng-Teng Ip, Vibe G. Frokjaer, Annamaria Giraldi, Martin Balslev Jørgensen, and Kristian H. Reveles Jensen.
URL: https://www.psypost.org/brain-waves-predict-sexual-side-effects-of-common-depression-medications/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #BrainWavesPredictSSRISideEffects #EEGLoudnessResponse #SerotoninActivityMarker #SexualSideEffectsPrediction #SSRIOrgasmDysfunction #DepressionTreatmentRisks #PersonalizedAntidepressants #AuditoryEvokedPotentials #PsychiatricResearch #MoodDisorderTreatmentInsights
-
DATE: September 17, 2026 at 08:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Brain waves predict sexual side effects of common depression medications
URL: https://www.psypost.org/brain-waves-predict-sexual-side-effects-of-common-depression-medications/
Measuring brain activity before starting depression medication might help doctors predict which patients will experience sexual side effects. A recent study shows that a specific brain wave pattern related to serotonin can forecast whether a patient will struggle to reach orgasm after taking common antidepressants. The research was published in the Journal of Psychiatric Research.
Depression often brings a host of challenging symptoms, with sexual difficulties being highly prevalent. Between 40 and 60 percent of people with major depressive disorder experience sexual disturbances as part of their condition. While treating depression can sometimes improve a person’s sex life as their mood lifts, the medications themselves frequently cause new problems.
Selective serotonin reuptake inhibitors, usually referred to as SSRIs, are the most common medications prescribed for depression. SSRIs work by increasing the availability of serotonin, a chemical messenger in the brain. Higher serotonin levels help alleviate depressive symptoms but also inhibit sexual function in many individuals.
Between 40 and 70 percent of patients taking SSRIs report adverse reactions such as diminished sexual desire, difficulty becoming aroused, or trouble reaching orgasm. These side effects can drastically affect a person’s quality of life and relationships. As a result, many patients stop taking their antidepressants altogether.
The study was conducted by researchers at the Copenhagen University Hospital and the University of Copenhagen. Gudrun Dilja Ketilsdottir and Kristian H. Reveles Jensen led the research team. They wanted to find a way to predict individual susceptibility to these side effects before a prescription is written.
The researchers focused on a biological marker called the loudness dependence of auditory evoked potentials. This marker is measured using an electroencephalogram, or EEG, which records electrical activity in the brain through sensors placed on the scalp. The measure tracks how the brain reacts to sounds of increasing volume.
Previous research suggests that this auditory brain response acts as an inverse indicator of serotonin activity in the central nervous system. A weaker brain response to louder sounds indicates higher baseline serotonin activity. The researchers hypothesized that people who already have high serotonin activity before starting medication might be pushed over a threshold by SSRIs, triggering sexual side effects.
The research team analyzed data from 90 unmedicated patients diagnosed with major depressive disorder. The participants were between the ages of 18 and 57, and roughly three-quarters of the group were women. None of the patients had taken antidepressant medication for at least two months prior to the study.
Before starting any treatment, each participant underwent an EEG recording. During this session, they listened to a series of tones at five different volume levels, ranging from 60 to 100 decibels. The researchers calculated the auditory brain response for each patient based on how their brain waves changed as the tones grew louder.
Alongside the brain scans, the researchers assessed each patient’s baseline sexual function using clinical questionnaires. They also measured blood levels of testosterone. Afterward, 86 of the participants began treatment with the SSRI escitalopram for eight weeks.
During the treatment period, clinicians monitored the patients for changes in their depression symptoms and the emergence of side effects. If a patient did not respond well to escitalopram or experienced intolerable side effects by week four, they were offered a switch to a different type of antidepressant called duloxetine. Seven patients made this switch.
At the end of the eight weeks, the clinicians formally rated the severity of any medication-induced sexual side effects. The researchers then ran statistical models to see if the pretreatment brain wave measurements corresponded to the side effects observed at the end of the trial.
The analysis revealed a robust link between baseline brain activity and later sexual difficulties. Patients who displayed a weaker brain response to increasing sound volume prior to treatment experienced higher rates of SSRI-induced orgasmic dysfunction. This specific brain wave pattern accurately predicted distressing orgasmic dysfunction 87 percent of the time.
The researchers also looked at whether the brain marker could predict a loss of sexual desire. They found a marginal association between the brain response and decreased libido, though it was not as strong as the link to orgasmic dysfunction. The brain marker was entirely unrelated to the occurrence of erectile dysfunction in the male participants.
When the team incorporated pretreatment blood testosterone levels into their predictive models, the changes in accuracy were not statistically significant. The auditory brain response alone, combined with basic demographic information and the patient’s baseline sexual function, was sufficient for predicting the side effects.
The researchers also examined the participants’ sexual function before any medication was introduced. They found that the auditory brain response was not associated with the level of sexual dysfunction caused directly by the depression itself. The brain marker appears specifically linked to how the body reacts to the introduction of the SSRI medication.
Because the biological mechanism for orgasm relies heavily on specific serotonin receptors, the researchers suggest that the brain marker is capturing the precise neurological pathway disrupted by SSRIs. In contrast, sexual desire involves a wider network of brain chemicals, which might explain why the brain marker was less predictive of decreased libido.
The study relied on an open-label design, meaning both the patients and the clinicians knew which medication was being administered. Without a placebo control group, some of the observed changes in sexual function could be related to natural fluctuations in the illness rather than the medication alone. The study participants were also relatively young, with an average age of 27.5 years, which may limit how well the findings apply to older adults.
Because a small portion of the group switched from escitalopram to duloxetine halfway through the trial, the results capture the effects of two different antidepressants. The researchers did perform a secondary analysis isolating only the patients on escitalopram, which produced the same outcome. Even so, testing the brain marker against a single medication in a more standardized protocol would provide firmer conclusions.
Moving forward, the research team aims to test this biological marker in more diverse groups of patients in standard clinical settings. If the auditory brain response proves reliable across broader populations, it could eventually serve as a routine screening tool. Doctors could use the test to identify patients at high risk for sexual side effects and prescribe alternative antidepressants that act on different brain chemicals.
The study, “Serotonergic activity estimated by EEG loudness-dependent auditory evoked potentials as a predictor of sexual SSRI side effects,” was authored by Gudrun Dilja Ketilsdottir, Cheng-Teng Ip, Vibe G. Frokjaer, Annamaria Giraldi, Martin Balslev Jørgensen, and Kristian H. Reveles Jensen.
URL: https://www.psypost.org/brain-waves-predict-sexual-side-effects-of-common-depression-medications/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #BrainWavesPredictSSRISideEffects #EEGLoudnessResponse #SerotoninActivityMarker #SexualSideEffectsPrediction #SSRIOrgasmDysfunction #DepressionTreatmentRisks #PersonalizedAntidepressants #AuditoryEvokedPotentials #PsychiatricResearch #MoodDisorderTreatmentInsights
-
DATE: September 17, 2026 at 08:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Brain waves predict sexual side effects of common depression medications
URL: https://www.psypost.org/brain-waves-predict-sexual-side-effects-of-common-depression-medications/
Measuring brain activity before starting depression medication might help doctors predict which patients will experience sexual side effects. A recent study shows that a specific brain wave pattern related to serotonin can forecast whether a patient will struggle to reach orgasm after taking common antidepressants. The research was published in the Journal of Psychiatric Research.
Depression often brings a host of challenging symptoms, with sexual difficulties being highly prevalent. Between 40 and 60 percent of people with major depressive disorder experience sexual disturbances as part of their condition. While treating depression can sometimes improve a person’s sex life as their mood lifts, the medications themselves frequently cause new problems.
Selective serotonin reuptake inhibitors, usually referred to as SSRIs, are the most common medications prescribed for depression. SSRIs work by increasing the availability of serotonin, a chemical messenger in the brain. Higher serotonin levels help alleviate depressive symptoms but also inhibit sexual function in many individuals.
Between 40 and 70 percent of patients taking SSRIs report adverse reactions such as diminished sexual desire, difficulty becoming aroused, or trouble reaching orgasm. These side effects can drastically affect a person’s quality of life and relationships. As a result, many patients stop taking their antidepressants altogether.
The study was conducted by researchers at the Copenhagen University Hospital and the University of Copenhagen. Gudrun Dilja Ketilsdottir and Kristian H. Reveles Jensen led the research team. They wanted to find a way to predict individual susceptibility to these side effects before a prescription is written.
The researchers focused on a biological marker called the loudness dependence of auditory evoked potentials. This marker is measured using an electroencephalogram, or EEG, which records electrical activity in the brain through sensors placed on the scalp. The measure tracks how the brain reacts to sounds of increasing volume.
Previous research suggests that this auditory brain response acts as an inverse indicator of serotonin activity in the central nervous system. A weaker brain response to louder sounds indicates higher baseline serotonin activity. The researchers hypothesized that people who already have high serotonin activity before starting medication might be pushed over a threshold by SSRIs, triggering sexual side effects.
The research team analyzed data from 90 unmedicated patients diagnosed with major depressive disorder. The participants were between the ages of 18 and 57, and roughly three-quarters of the group were women. None of the patients had taken antidepressant medication for at least two months prior to the study.
Before starting any treatment, each participant underwent an EEG recording. During this session, they listened to a series of tones at five different volume levels, ranging from 60 to 100 decibels. The researchers calculated the auditory brain response for each patient based on how their brain waves changed as the tones grew louder.
Alongside the brain scans, the researchers assessed each patient’s baseline sexual function using clinical questionnaires. They also measured blood levels of testosterone. Afterward, 86 of the participants began treatment with the SSRI escitalopram for eight weeks.
During the treatment period, clinicians monitored the patients for changes in their depression symptoms and the emergence of side effects. If a patient did not respond well to escitalopram or experienced intolerable side effects by week four, they were offered a switch to a different type of antidepressant called duloxetine. Seven patients made this switch.
At the end of the eight weeks, the clinicians formally rated the severity of any medication-induced sexual side effects. The researchers then ran statistical models to see if the pretreatment brain wave measurements corresponded to the side effects observed at the end of the trial.
The analysis revealed a robust link between baseline brain activity and later sexual difficulties. Patients who displayed a weaker brain response to increasing sound volume prior to treatment experienced higher rates of SSRI-induced orgasmic dysfunction. This specific brain wave pattern accurately predicted distressing orgasmic dysfunction 87 percent of the time.
The researchers also looked at whether the brain marker could predict a loss of sexual desire. They found a marginal association between the brain response and decreased libido, though it was not as strong as the link to orgasmic dysfunction. The brain marker was entirely unrelated to the occurrence of erectile dysfunction in the male participants.
When the team incorporated pretreatment blood testosterone levels into their predictive models, the changes in accuracy were not statistically significant. The auditory brain response alone, combined with basic demographic information and the patient’s baseline sexual function, was sufficient for predicting the side effects.
The researchers also examined the participants’ sexual function before any medication was introduced. They found that the auditory brain response was not associated with the level of sexual dysfunction caused directly by the depression itself. The brain marker appears specifically linked to how the body reacts to the introduction of the SSRI medication.
Because the biological mechanism for orgasm relies heavily on specific serotonin receptors, the researchers suggest that the brain marker is capturing the precise neurological pathway disrupted by SSRIs. In contrast, sexual desire involves a wider network of brain chemicals, which might explain why the brain marker was less predictive of decreased libido.
The study relied on an open-label design, meaning both the patients and the clinicians knew which medication was being administered. Without a placebo control group, some of the observed changes in sexual function could be related to natural fluctuations in the illness rather than the medication alone. The study participants were also relatively young, with an average age of 27.5 years, which may limit how well the findings apply to older adults.
Because a small portion of the group switched from escitalopram to duloxetine halfway through the trial, the results capture the effects of two different antidepressants. The researchers did perform a secondary analysis isolating only the patients on escitalopram, which produced the same outcome. Even so, testing the brain marker against a single medication in a more standardized protocol would provide firmer conclusions.
Moving forward, the research team aims to test this biological marker in more diverse groups of patients in standard clinical settings. If the auditory brain response proves reliable across broader populations, it could eventually serve as a routine screening tool. Doctors could use the test to identify patients at high risk for sexual side effects and prescribe alternative antidepressants that act on different brain chemicals.
The study, “Serotonergic activity estimated by EEG loudness-dependent auditory evoked potentials as a predictor of sexual SSRI side effects,” was authored by Gudrun Dilja Ketilsdottir, Cheng-Teng Ip, Vibe G. Frokjaer, Annamaria Giraldi, Martin Balslev Jørgensen, and Kristian H. Reveles Jensen.
URL: https://www.psypost.org/brain-waves-predict-sexual-side-effects-of-common-depression-medications/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #BrainWavesPredictSSRISideEffects #EEGLoudnessResponse #SerotoninActivityMarker #SexualSideEffectsPrediction #SSRIOrgasmDysfunction #DepressionTreatmentRisks #PersonalizedAntidepressants #AuditoryEvokedPotentials #PsychiatricResearch #MoodDisorderTreatmentInsights